PL2184059T3 - Polimery wiążące potas do zastosowania w terapeutycznym lub profilaktycznym sposobie leczenia hiperkalemii - Google Patents

Polimery wiążące potas do zastosowania w terapeutycznym lub profilaktycznym sposobie leczenia hiperkalemii

Info

Publication number
PL2184059T3
PL2184059T3 PL10152337T PL10152337T PL2184059T3 PL 2184059 T3 PL2184059 T3 PL 2184059T3 PL 10152337 T PL10152337 T PL 10152337T PL 10152337 T PL10152337 T PL 10152337T PL 2184059 T3 PL2184059 T3 PL 2184059T3
Authority
PL
Poland
Prior art keywords
therapeutic
hyperkalemia
potassium
binding polymers
prophylactic method
Prior art date
Application number
PL10152337T
Other languages
English (en)
Polish (pl)
Inventor
Dominique Charmot
Han Ting Chang
Gerrit Klaerner
Michael James Cope
Mingjun Liu
Futian Liu
Tony Kwok-Kong Mong
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2184059(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Application filed by Relypsa Inc filed Critical Relypsa Inc
Priority claimed from EP05732849A external-priority patent/EP1732523B9/en
Publication of PL2184059T3 publication Critical patent/PL2184059T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Dental Preparations (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
PL10152337T 2004-03-30 2005-03-30 Polimery wiążące potas do zastosowania w terapeutycznym lub profilaktycznym sposobie leczenia hiperkalemii PL2184059T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
EP10152337A EP2184059B1 (en) 2004-03-30 2005-03-30 Potassium-binding polymers for use in a therapeutic or prophylactic method for treating hyperkalemia
EP05732849A EP1732523B9 (en) 2004-03-30 2005-03-30 Potassium binding polymers and uses thereof

Publications (1)

Publication Number Publication Date
PL2184059T3 true PL2184059T3 (pl) 2013-01-31

Family

ID=40774830

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10152337T PL2184059T3 (pl) 2004-03-30 2005-03-30 Polimery wiążące potas do zastosowania w terapeutycznym lub profilaktycznym sposobie leczenia hiperkalemii
PL16203827T PL3219312T3 (pl) 2004-03-30 2005-03-30 Polimery wiążące jon i ich zastosowania
PL10186212T PL2269589T3 (pl) 2004-03-30 2005-03-30 Polimery wiążące jony i ich zastosowania

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL16203827T PL3219312T3 (pl) 2004-03-30 2005-03-30 Polimery wiążące jon i ich zastosowania
PL10186212T PL2269589T3 (pl) 2004-03-30 2005-03-30 Polimery wiążące jony i ich zastosowania

Country Status (13)

Country Link
EP (6) EP2269590A3 (enExample)
JP (4) JP5600658B2 (enExample)
KR (5) KR101223335B1 (enExample)
CN (2) CN103251571B (enExample)
AT (2) ATE460927T1 (enExample)
AU (5) AU2010214729B2 (enExample)
CA (2) CA2829943C (enExample)
DE (4) DE602005019992D1 (enExample)
DK (2) DK2269589T3 (enExample)
ES (6) ES2388052T3 (enExample)
GB (2) GB2456256B (enExample)
PL (3) PL2184059T3 (enExample)
PT (3) PT3219312T (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795755B2 (en) 2012-07-11 2017-10-24 Koninklijke Philips N.V. Patient interface
KR102674230B1 (ko) * 2014-12-23 2024-06-11 알데릭스, 인코포레이티드 고칼륨혈증의 치료를 위한 조성물 및 방법
CN213938270U (zh) * 2020-04-03 2021-08-10 南京西觉硕信息科技有限公司 一种音频设备
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN117106852B (zh) * 2023-09-04 2024-03-19 济宁市兖州区检验检测中心 一种快速检测农产品农药残留的检测方法及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3031737A1 (de) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse
KR920006865B1 (ko) 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
CN1010098B (zh) * 1985-05-25 1990-10-24 赫彻斯特股份公司 α-氟代丙烯酸酯聚合物的制备方法
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
FR2634377B1 (fr) * 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
DE4139747A1 (de) * 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Fuellstoffhaltige, optisch aktive perlpolymerisate
EP0684958B1 (en) 1993-02-17 1998-06-10 Btg International Limited Polymers containing guanidino groups for use in therapy
WO1994027619A1 (en) * 1993-05-20 1994-12-08 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) * 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
WO1996021454A1 (en) 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
GB9503061D0 (en) 1995-02-16 1995-04-05 British Tech Group Polymeric compounds
EP0793960B1 (en) 1996-03-05 2001-08-01 Mitsubishi Chemical Corporation Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
CN1230118A (zh) 1996-07-19 1999-09-29 日研化学株式会社 高磷血症治疗剂
WO1998017707A1 (en) 1996-10-23 1998-04-30 The Dow Chemical Company Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption
AU2446497A (en) 1997-03-25 1998-10-20 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers combined with a calcium supplement for oral administration
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
JP2001526212A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
CA2355829A1 (en) * 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
DE60027309T2 (de) 1999-07-02 2006-08-31 Symyx Technologies, Inc., Santa Clara Polymerverzweigungen zur immobilisierung von molekülen auf oberflächen oder substraten, wobei die polymere wasserlösliche oder wasserdispergierbare segmente und sonden aufweisen
KR20020026366A (ko) 1999-08-09 2002-04-09 한스 루돌프 하우스, 헨리에데 부르너 단백질의 생산
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
KR100794427B1 (ko) 1999-10-19 2008-01-16 젠자임 코포레이션 직접 압축형 중합체 정제 코어
US6908609B2 (en) 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
BR0209020A (pt) 2001-04-18 2004-08-10 Genzyme Corp Composição farmacêutica de polialilamina
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
KR101153035B1 (ko) * 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물

Also Published As

Publication number Publication date
EP2269590A3 (en) 2011-10-05
JP2014040484A (ja) 2014-03-06
EP3574896A1 (en) 2019-12-04
AU2018206706B2 (en) 2020-08-06
GB2456256A (en) 2009-07-15
EP2269589A2 (en) 2011-01-05
DE602005018619D1 (de) 2010-02-11
EP2269590A2 (en) 2011-01-05
HK1106133A1 (en) 2008-03-07
PT3219312T (pt) 2019-03-01
EP3219312B1 (en) 2019-01-30
DK2269589T3 (da) 2014-03-31
ES2720612T3 (es) 2019-07-23
EP2269589A3 (en) 2011-10-05
KR20110138300A (ko) 2011-12-26
EP2158902B1 (en) 2017-12-06
PT2269589E (pt) 2014-02-26
AU2016216697B2 (en) 2018-04-19
DE112005000725B4 (de) 2017-12-21
GB2456253B (en) 2009-08-26
JP5431439B2 (ja) 2014-03-05
ES2339571T3 (es) 2010-05-21
EP3219312A1 (en) 2017-09-20
JP5671511B2 (ja) 2015-02-18
CN103251571B (zh) 2016-08-17
KR101362509B1 (ko) 2014-02-13
AU2016216697A1 (en) 2016-09-08
GB0906966D0 (en) 2009-06-03
GB2456253A (en) 2009-07-15
HK1109338A1 (en) 2008-06-06
KR20140003661A (ko) 2014-01-09
AU2018206706A1 (en) 2018-08-02
KR101399238B1 (ko) 2014-05-27
CN102133196A (zh) 2011-07-27
KR20130086262A (ko) 2013-07-31
EP2184059A3 (en) 2010-05-19
CA2829943A1 (en) 2005-10-20
GB0907161D0 (en) 2009-06-10
AU2010214732B2 (en) 2012-07-12
EP2158902A1 (en) 2010-03-03
ES2338667T3 (es) 2010-05-11
ES2453048T3 (es) 2014-04-03
AU2012254879A1 (en) 2012-12-13
PL3219312T3 (pl) 2019-07-31
PT2184059E (pt) 2012-07-06
KR101269766B1 (ko) 2013-05-30
PL2269589T3 (pl) 2014-05-30
GB2456256B (en) 2009-08-26
AU2010214732A1 (en) 2010-09-23
JP2013056909A (ja) 2013-03-28
DK3219312T3 (en) 2019-04-01
CA2806465A1 (en) 2005-10-20
CN102133196B (zh) 2015-01-21
EP2184059A2 (en) 2010-05-12
EP2269589B1 (en) 2013-12-25
JP2012025783A (ja) 2012-02-09
DE112005000708T5 (de) 2007-02-15
DE112005000725T5 (de) 2007-05-03
DE112005000708B4 (de) 2017-12-21
KR20120060920A (ko) 2012-06-12
ES2659386T3 (es) 2018-03-15
DE602005019992D1 (de) 2010-04-29
ATE460927T1 (de) 2010-04-15
KR101223335B1 (ko) 2013-01-17
ES2388052T3 (es) 2012-10-08
EP2184059B1 (en) 2012-06-27
CN103251571A (zh) 2013-08-21
CA2829943C (en) 2017-03-14
AU2012254879B2 (en) 2016-05-19
AU2010214729B2 (en) 2012-08-16
AU2016216697C1 (en) 2019-03-21
JP2012031210A (ja) 2012-02-16
JP5600658B2 (ja) 2014-10-01
KR20120130255A (ko) 2012-11-29
AU2010214729A1 (en) 2010-09-23
CA2806465C (en) 2016-05-24
ATE453383T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
GB2430368B (en) Methods and compositions for treatment of ion imbalances
WO2005092039A3 (en) Crosslinked amine polymers
GB2446076A (en) Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007136969A3 (en) Bioabsorbable magnesium-reinforced polymer stents
GB2446077A (en) Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
EP1831266A4 (en) RETICULATED AMINE POLYMERS
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2007038801A3 (en) Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
GB2456256B (en) Ion binding compositions
WO2004018010A3 (en) Methods of drug delivery using sulphated chitinous polymers
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2006078875A3 (en) A method for treating neurologic diseases
WO2009018429A3 (en) TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2
WO2008070778A3 (en) Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
WO2007062048A3 (en) Role of proteoglycans in drug dependence
WO2007017652A3 (en) Arylakylamines for the treatment of cancer
TW200635580A (en) Methods of treatment and prevention
AU2004901949A0 (en) In-Line Treatment System and Process